Showing results (101-110 of 184) with videos related to

Sort By:
Pageof 19
Alimentary Pharmacology & Therapeutics|July 20, 2007
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitisC W Lees, D Heys, G T Ho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's DiseaseNikolas Plevris, James Fulforth, Mathew Lyons, et al.
Journal of Crohn'S & Colitis|August 20, 2014
Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 yearsNicholas A Kennedy, Annalie Clark, Andrew Walkden, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Journal of the American Chemical Society|August 2, 2022
Direct H<sub>2</sub>O<sub>2</sub> Synthesis, without H<sub>2</sub> GasAoxue Huang, Roxanna S Delima, Yongwook Kim, et al.
Journal of Crohn'S & Colitis|August 24, 2023
Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT datasetRebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
The use of adalimumab in the management of refractory Crohn's diseaseG-T Ho, L Smith, S Aitken, et al.
Inflammatory Bowel Diseases|February 21, 2018
The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal DiseaseNicholas A Kennedy, Christopher A Lamb, Susan H Berry, et al.
Pageof 19